Why SOUN, INFA, and TWLO Stock Plunged
The artificial intelligence bubble for speculative stocks popped. While Nvidia (NVDA) is the exception to a sell-off for AI stocks, its sale of SoundHound AI (SOUN) sent the stock down by 28.1% last Friday.Nvidia filed a 13-F that indicated the firm closed its position on SoundHound AI, Nano-X (NNOX), and Serve Robotics (SERV). Nvidia also sold some of its Arm Holdings (ARM) shares. Investors should be wary of SERV stock. The robotic solution for delivering goods is not attractive, since it lacks a moat.Informatica (INFA) lost 24% of its value after posting Q4/2024 results. Revenue fell by 3.8% Y/Y to $428.3 million. The CEO said that the company is in the final stages of its cloud-only transformation.To support its share price, Informatica added $400 million to its stock buyback program. The total authorization is $400 million.Communications software firm Twilio (TWLO) retreated by 15% to close at $125.17. It earned $1.00 in non-GAAP EPS. Despite strong Y/Y improvement in income and revenue growth of 10.2% to $1.19 billion, investors expected more.The company has strong bookings growth. New bookings are tied to multiyear deals, so the customer growth will not show up until later quarterly reporting periods.Among the stocks mentioned above, TWLO stock is the most attractive. It has strong growth, profitability, and positive stock momentum. Analysts will continue to hold or even raise their earnings forecast for Twilio.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


